rafael pharmaceuticals news
To extend and enhance the lives of patients with Gastrointestinal (GI) Cancers. Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who are working with Rafael to revolutionize anticancer treatment. About Rafael Pharmaceuticals, Inc. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc. and LipoMedix Pharmaceuticals Ltd. The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals… Rafael Holdings is focused on development of novel cancer therapies. This report provides comprehensive insights about 6+ … Get the latest RAFARMA PHARMACEUTICALS INC (RAFA) stock news and headlines to help you in your trading and investing decisions. Rafael Pharmaceuticals is a leader in the growing field of cancer metabolism. RAFA | Complete Rafarma Pharmaceuticals Inc. stock news by MarketWatch. Yerba Santa helps provide enhanced moisturization and lubricity, in a manner similar to Aloe Vera. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attack hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Executive … Clear Cell Sarcoma - Pipeline Insight, 2021: Featuring Key Players Tesaro, NantPharma, Rafael Pharmaceuticals and Pfizer - ResearchAndMarkets.com February 09, … Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma.. Soft tissue sarcoma is a type of cancer that starts in the soft tissues of the body, such as fat, muscle, nerves, fibrous tissues, blood vessels or deep skin tissues. Rafael Pharmaceuticals is a pioneering, clinical-late stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers in both solid and hem malignancies by applying our deep understanding of the unique … Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017, Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613® in Acute Myeloid Leukemia (AML) and T-Cell Non-Hodgkin’s Lymphoma (T-cell NHL) at ASH 2016, Cornerstone Pharmaceuticals Appoints Brian Mullaney, M.D., Ph.D., as Chief Medical Officer, Cornerstone Pharmaceuticals to Present New Data on CPI-613® at the American Society of Hematology 2016 Annual Meeting, IDT Corporation Announces Investment in Cornerstone Pharmaceuticals, Cornerstone Pharmaceuticals Announces Acceptance of Abstract on CPI-613® Pancreatic Cancer Trial by European Society for Medical Oncology (ESMO) Congress 2016, Cornerstone Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, Cornerstone Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613® in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium, Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613® in Combination with High Dose Ara-C (HDAC) and Mitoxantrone in Relapsed or Refractory Acute Myeloid Leukemia to Be Presented at 57th Annual ASH Meeting, Cornerstone Pharmaceuticals Receives Funding through New Jersey’s Technology Business Tax Certificate Transfer Program, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Metastatic Colorectal Cancer, Cornerstone Pharmaceuticals Commences Phase I Clinical Trial of CPI-613® for the Treatment of B-Cell Non-Hodgkin Lymphoma, Cornerstone Pharmaceuticals’ CPI-613® Selected as One of Informa and Kantar Health 2014 Top 10 Most Interesting Oncology Projects to Watch, Cornerstone Pharmaceuticals Announces Positive Phase I Data for CPI-613® in Relapsed or Refractory AML Patients to be Presented at 2014 ASH Annual Meeting, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Hodgkin’s or T-Cell Non-Hodgkin’s Lymphoma, Cornerstone Pharmaceuticals Appoints Steve Carchedi Chief Executive Officer, Cornerstone Pharmaceuticals’ CPI-613® Phase I Hematologic Malignancies Trial Data Published in AACR’s Clinical Cancer Research, Cornerstone Pharmaceuticals Clinical Data on CPI-613® to be Presented at ASCO 2014, Cornerstone Pharmaceuticals’ CPI-613® Data to be Presented at the 2014 Annual American Society of Clinical Oncology (ASCO) Meeting, Cornerstone Pharmaceuticals Lead Compound CPI-613® Demonstrates Ability to Disrupt Growth of Cancer Cells, Cornerstone Pharmaceuticals Presents Non-Small Cell Lung Cancer Data for CPI-613® at 2014 Special Conference of American Association for Cancer Research, Cornerstone Pharmaceuticals Appoints Dr. Chi Van Dang to Scientific Advisory Board, Cornerstone Pharmaceuticals Presents Updated Phase I Data for CPI-613® at 2013 American Society of Hematology Annual Meeting, Cornerstone Pharmaceuticals to Present on Cancer Metabolism at Target TME 2013 Workshop, Cornerstone Pharmaceuticals to Present CPI-613® Phase I Results at 2013 American Society of Hematology Annual Meeting, Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® in Patients with Locally Advanced or Metastatic Pancreatic Cancer, Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613® for the Treatment of Small Cell Lung Cancer, Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613® for Treatment of Myelodysplastic Syndrome, Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® for the Treatment of Myelodysplastic Syndrome, Cornerstone Pharmaceuticals Appoints Dr. Sim Fass and Howard Jonas to Board of Directors, Cornerstone Pharmaceuticals Initiates Phase I Clinical Trial of CPI-613® for the Treatment of Acute Myelogenous Leukemia, Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® for the Treatment of Advanced Bile Duct Cancers, Cornerstone Pharmaceuticals Presents Data at 2013 Annual ASCO Meeting, Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613® in Patients with Advanced Solid Tumors, Cornerstone Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of CPI-613® with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer, Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at the Tenth Annual Discovery On Target Conference in Boston regarding cancer cell metabolism, Cornerstone Pharmaceuticals announces speaking engagement of Dr. Paul Bingham at BioX 2012 Conference, Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual ASCO Meeting, Cornerstone Pharmaceuticals announces publication of case report on treatment of a patient presenting metastatic pancreatic cancer with CPI-613 and gemcitabine combination therapy, Cornerstone Pharmaceuticals announces presentations regarding its proprietary anticancer compound CPI-613® at 2012 Annual AACR Meeting, Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613®, showing promise in Phase I trial for acute myeloid leukemia, Cornerstone Pharmaceuticals to present at the 9th Annual Discovery on Target Meetings in Boston, Cornerstone Pharmaceuticals publishes positive pre-clinical study results comparing its proprietary drug EmPAC™ to Taxol® in the Journal of Nanoscience and Nanotechnology, Cornerstone Pharmaceuticals announces FDA orphan drug designation of CPI-613® for patients with acute myeloid leukemia, Cornerstone Pharmaceuticals announces the Journal of Molecular Medicine’s publication of research showing selective inhibition of cancer cell energy metabolism with its novel lipoate derivative compounds, Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613® in Acute Myeloid Leukemia, Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study, Cornerstone Pharmaceuticals Awarded $490K in Grants Under QTDP Program, Cornerstone Pharmaceuticals Presents Interim Phase I Data at the European Society of Medical Oncology Annual Conference, Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences, Cornerstone Pharmaceuticals Appoints Dr. Dorit Arad Director of Research and Development for its Israeli Operations, Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First-in-Class Anti-Cancer Agent CPI-613®, Cornerstone Pharmaceuticals Appoints Timothy Sullivan Executive Vice President and Head of Corporate Development, Cornerstone Pharmaceuticals Partners with Wake Forest University on Clinical Trial of CP-613® for Hematologic Malignancies, Cornerstone Pharmaceuticals Enters Into a Collaboration Agreement with the U.S. National Cancer Institute, Dr. Robert Shepard Appointed Chief Medical Officer for Cornerstone Pharmaceuticals, Cornerstone Pharmaceuticals Adds New Clinical Trial Site for the Evaluation of its First- In-Class Anti-Cancer Agent CPI-613®, Cornerstone Pharmaceuticals Chosen Among Top 10 Most Interesting Oncology Projects, Leading Oncologist Dr. Robert Shepard Joins Cornerstone Pharmaceuticals as Acting Chief Medical Officer, Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D., to its Scientific Advisory Board, Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial of CPI-613® for Treatment of Pancreatic Cancer, Cornerstone Pharmaceuticals Announces $6M Financing to Further Advance Clinical Trials in Cancer Patients, Cornerstone Pharmaceuticals Announces Initiation of Clinical Trials of CPI-613® for the Treatment of Cancer, Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I / II Clinical Trial of CPI-613® in Cancer Patients by US FDA. News Break; rafael pharmaceuticals. © 2021 Rafael Pharmaceuticals, Inc. All Rights Reserved, Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference, Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference, Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue, Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer, FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma, Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML), A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan, Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models, Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer, MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia, Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML), Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ️ (devimistat) for Patients with Metastatic Pancreatic Cancer, Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Company profile page for Rafael Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Rafael Pharmaceuticals To Save a Life Is To Save A Universe ™ It has been known for nearly a century that cancer cells have a unique metabolism compared to normal cells. CPI-613® is being evaluated in multiple Phase I, I/II, II, and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. Rafael’s lead AMD compound, CPI-613 ® (devimistat), is being evaluated in 19 ongoing or completed Phase I, I/II, II and III clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. Please check the website periodically for available positions. Rafael Holdings Navigation.